



L7 ANSWER 406 OF 478 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:6295 CAPLUS
 DN 96:6295
 TI Synthesis and pharmacological studies of some (amino-alkyl) phenylsulfones
 AU Moreau, R. C.; Fournier, J. P.; Narcisse, G.; Bakri-Logeais, F.; Choay, P.
 CS Lab. Pharm. Chim., Fac. Sci. Pharm. Biol., Paris, F-75270/06, Fr.
 SO Annales Pharmaceutiques Francaises (1981), 39(3), 283-90
 CODEN: APFRAD; ISSN: 0003-4509
 DT Journal
 LA French
 GI



AB Sulfones I ($n = 2, 3$; $R = Et$, or $NR2 = piperidino$, $pyrrolidino$, $morpholino$; $R1 = H$, Cl) showed antiarrhythmic, antiemetic, and anti-ulcer activity and they were prep'd. from the resp. chloroalkyl sulfones and amines. Thus, a mixt. of $2\text{-MeOC}_6\text{H}_4\text{SO}_2\text{CH}_2\text{CH}_2\text{Cl}$ and excess piperidine in Me_2CHOH was refluxed to give I ($n = 2$, $NR2 = piperidino$, $R1 = H$).
 IT 74254-72-1P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 74254-72-1 CAPLUS
 CN Pyrrolidine, 1-[3-[(2-methoxyphenyl)sulfonyl]propyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 74254-71-0
 CMF C14 H21 N O3 S




CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7



103. *Nur Me*


L7 ANSWER 395 OF 478 CAPLUS COPYRIGHT 2003 ACS
AN 1983:16264 CAPLUS
DN 98:16264
TI Alkylations of trialkylsulfonyldiamides
AU Unterhalt, Bernard; Seebach, Edmar
CS Inst. Pharm. Chem., Univ. Marburg, Marburg/Lahn, D-3550, Fed. Rep. Ger.
SO Archiv der Pharmazie (Weinheim, Germany) (1982), 315(10), 852-7
CODEN: ARP MAS; ISSN: 0365-6233
DT Journal
LA German
OS CASREACT 98:16264
AB Me₂NSO₂NHMe reacted with ClCH₂OEt or ClCH₂R₁ (R₁ = SMe, SPr, SBu) under conditions of phase transfer catalysis (PhCH₂N+Me₃.Cl-) to give 38% Me₂NSO₂NRCH₂R₁ (I; R = Me, R₁ = OEt) and 22-42% I (R = Me, R₁ = SMe, SPr, SBu). Aminomethylation with HCHO and secondary amines gave 53-65% I (R = Me, R₁ = NMe₂, NET₂, piperidino, morpholino). Although ClCH₂CH₂OCH₂Ph did not react, 19-75% I [R = Me, R₁ = CH₂SET, CH₂SCH₂Ph, CH₂NMe₂, CH₂NET₂, CH₂N(CHMe₂)₂, 1-pyrrolidinylmethyl, piperidinomethyl] could be obtained. Me₂NSO₂NHCH₂Ph and ClCH₂OEt gave 20% I (R = CH₂Ph, R₁ = OEt), Et₂NSO₂NHMe, HCHO, and Me₂NH gave 72% Et₂NSO₂NMeCH₂NMe₂, and Me₂NSO₂NNaMe or Me₂NSO₂NNaEt with Cl(CH₂)₃NET₂ gave 90 and 85% I (R = Me, Et; R₁ = CH₂CH₂NET₂).
IT 83961-42-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 83961-42-6 CAPLUS
CN Sulfamide, trimethyl[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 396 OF 478 CAPLUS COPYRIGHT 2003 ACS
AN 1982:555924 CAPLUS
DN 97:155924
TI Synthetic inhibitors of serine proteinases. Part 26. Inhibition of trypsin, plasmin and thrombin by amides of N.α.-arenesulfonylated 2-amino-4-(4-amidinophenyl)butyric and 2-amino-5-(amidinophenyl)valeric acids
AU Stuerzebecher, J.; Markwardt, F.; Vieweg, H.; Wagner, G.; Walsmann, P.
CS Inst. Pharmakol. Toxikol., Med. Akad. Erfurt, Erfurt, DDR-5060, Ger.
Dem.
Rep.
SO Pharmazie (1982), 37(4), 281-3
CODEN: PHARAT; ISSN: 0031-7144

122

L7 ANSWER 406 OF 478 CAPLUS COPYRIGHT 2003 ACS
AN 1982:6295 CAPLUS
DN 96:6295
TI Synthesis and pharmacological studies of some (amino-alkyl) phenylsulfones
AU Moreau, R. C.; Fournier, J. P.; Narcisse, G.; Bakri-Logeais, F.; Choay, P.
CS Lab. Pharm. Chim., Fac. Sci. Pharm. Biol., Paris, F-75270/06, Fr.
SO Annales Pharmaceutiques Francaises (1981), 39(3), 283-90
CODEN: APFRAD; ISSN: 0003-4509
DT Journal
LA French
GI




I

AB Sulfones I (n = 2,3; R = Et, or NR₂ = piperidino, pyrrolidino, morpholino; R₁ = H, Cl) showed antiarrhythmic, antiemetic, and anti-ulcer activity and they were prepd. from the resp. chloroalkyl sulfones and amines. Thus, a mixt. of 2-MeOC₆H₄SO₂CH₂CH₂Cl and excess piperidine in Me₂CHOH was refluxed to give I (n = 2, NR₂ = piperidino, R₁ = H).
IT **74254-72-1P**
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
RN 74254-72-1 CAPLUS
CN Pyrrolidine, 1-[3-[(2-methoxyphenyl)sulfonyl]propyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 74254-71-0
CMF C₁₄ H₂₁ N O₃ S



CM 2

CRN 88-89-1
CMF C₆ H₃ N₃ O₇



L7 ANSWER 410 OF 478 CAPLUS COPYRIGHT 2003 ACS

AN 1981:461769 CAPLUS

DN 95:61769

TI Benzenesulfone derivatives and their use

IN Fournier, Jean Paul; Loiseau, Philippe

PA Choay S. A., Fr.

SO Fr. Demande, 19 pp.

CODEN: FRXXBL



DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2447909	A1	19800829	FR 1979-2572	19790131
	FR 2447909	B1	19821029		
PRAI	FR 1979-2572		19790131		

GI



II

AB Sulfones I (R = H, alkyl, Cl, oxoalkyl, oxoaryl, optionally esterified CO2H, amino; R1-R5 = H, halogen, NO2, NH2, Me, OMe; n = 1-3) were prep'd. Thus, 5,2-Cl(MeO)C6H3NH2 was diazotized and thiolated and the thiol treated with BrCH2CH2Cl to give 5,2-Cl(MeO)C6H3SCH2CH2Cl which was treated with piperidine to give II. Various I had antitumor, antiemetic, hypoglycemic, anticonvulsant, anticoagulant, antiulcer and antifibrillatory activity.

IT 74254-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)


RN 74254-72-1 CAPLUS

CN Pyrrolidine, 1-[3-[(2-methoxyphenyl)sulfonyl]propyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74254-71-0


CMF C14 H21 N O3 S




CM 2

CRN 88-89-1

CMF C6 H3 N3 O7





=> d 11; d his; log y
L1 HAS NO ANSWERS
L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

(FILE 'STNGUIDE' ENTERED AT 16:02:34 ON 18 APR 2003)
DEL HIS Y


FILE 'REGISTRY' ENTERED AT 16:03:19 ON 18 APR 2003
L1 STRUCTURE uploaded
L2 6371967 S 2-4/N AND 1-4/NR AND 1-2/NC
L3 50 S L1 SAM SUB=L2
L4 STRUCTURE uploaded
L5 50 S L4 SAM SUB=L2
L6 2571 S L4 FUL SUB=L2

FILE 'CPLUS' ENTERED AT 16:07:47 ON 18 APR 2003
L7 478 S L6


COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2174.88	2339.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-311.18	-311.18

STN INTERNATIONAL LOGOFF AT 16:17:35 ON 18 APR 2003


(CA
INDEX NAME)



L7 ANSWER 306 OF 478 CAPLUS COPYRIGHT 2003 ACS
AN 1991:607937 CAPLUS
DN 115:207937
TI Addition of lithium reagents of N,N-dialkylsulfonamides to Mannich bases
AU Mladenova, M.; Biserkova, M.; Stanchev, S.
CS Inst. Org. Chem., Sofia, 1113, Bulg.
SO Synthetic Communications (1991), 21(15-16), 1555-65
CODEN: SYNCAN; ISSN: 0039-7911
DT Journal
LA English
OS CASREACT 115:207937
GI




AB The addn. of metalated N,N-dialkylsulfonamides to Mannich bases leading to N,N-dialkylamides of 4-(N',N'-dialkylamino)-2-hydroxy-2-phenylbutanesulfonic acids is described. Thus, LiCH₂SO₂NMe₂ reacted with morpholinopropiophenone I to give 80% the hydroxy(morpholino)phenylbutanesulfonamide II.
IT 136877-30-0P 136877-39-9P 136877-40-2P
136877-41-3P 136877-42-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 136877-30-0 CAPLUS
CN 1-Pyrrolidinebutanesulfonamide, .beta.-hydroxy-N,N-dimethyl-.beta.-phenyl-
(9CI) (CA INDEX NAME)



RN 136877-39-9 CAPIUS

CN 1-Pyrrolidinebutanesulfonamide, .beta.-hydroxy-.alpha.-trimethyl-.beta.-phenyl-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 136877-40-2 CAPIUS

CN 1-Pyrrolidinebutanesulfonamide, .beta.-hydroxy-N,N-dimethyl-.alpha.,.beta.-diphenyl-, (R*,R*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 136877-41-3 CAPIUS

CN 1-Pyrrolidinebutanesulfonamide, .beta.-hydroxy-.alpha.-trimethyl-.beta.-phenyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 136877-42-4 CAPIUS

CN 1-Pyrrolidinebutanesulfonamide, .beta.-hydroxy-N,N-dimethyl-.alpha.,.beta.-

diphenyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 307 OF 478 CAPLUS COPYRIGHT 2003 ACS
AN 1991:583973 CAPLUS
DN 115:183973
TI Preparation of cyclic pentapeptides as endothelin antagonists
IN Ishikawa, Kiyofumi; Fukami, Takehiro; Hayama, Takashi; Niiyama, Kenji; Nagase, Toshio; Mase, Toshiaki; Fujita, Kagari; Nishikibe, Masaru; Ihara, Masaki; Yano, Mitsuo
PA Banyu Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 436189	A1	19910710	EP 1990-124947	19901220
	EP 436189	B1	19930728		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 04261198	A2	19920917	JP 1990-340804	19901130
	JP 3128822	B2	20010129		
	CA 2032559	AA	19910629	CA 1990-2032559	19901218
	CA 2032559	C	20011106		
	AU 9068285	A1	19910711	AU 1990-68285	19901219
	AU 632193	B2	19921217		
	US 5114918	A	19920519	US 1990-630505	19901220
	AT 92079	E	19930815	AT 1990-124947	19901220
	ES 2041611	T3	19941116	ES 1990-124947	19901220
PRAI	JP 1989-342695	A	19891228		
	JP 1990-185867	A	19900713		
	JP 1990-321532	A1	19901126		
	EP 1990-124947	A	19901220		
OS	MARPAT 115:183973				
AB	Cyclo(X1-X2-X3-X4-X5) [X1 = D-Trp, D-Phe, D-Tyr, D-3-(2-thienyl)alanyl, D-3-(2-thiazolyl)alanyl, etc.; X2 = D-Asp, D-Glu, D-cysteic acid residue; X3 = Pro, 4-hydroxyproyl, pipecolinic acid residue, Gly, Ala, Val, Leu, Ile, Met, Phe, Tyr, Trp, His, Arg, Lys, Orn, Asn, Gln, Asp, Glu, Cys, Ser, Thr, etc.; X4 = D-Ala, D-Thr, D-Val, D-Leu, D-norvalyl, D-.alpha.-aminobutanoic acid residue, 1-aminocyclopropanecarboxylic acid residue, etc.; X5 = Pro, His, Ala, Val, Leu, Ile, Met, L-pipecolic acid residue, L-thiazolidine-4-carboxylic acid residue, L-.alpha.-				

L7 ANSWER 414 OF 478 CAPLUS COPYRIGHT 2003 ACS

AN 1980:471289 CAPLUS

DN 93:71289

TI Phenyl alkyl sulfones

IN Fournier, Jean Paul; Loiseau, Philippe

PA Choay S. A., Fr.

SO Eur. Pat. Appl., 27 pp.


CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 8269	A1	19800220	EP 1979-400545	19790801
	EP 8269	B1	19840201		
	R: BE, CH, DE, GB, IT, NL				
	FR 2432316	A1	19800229	FR 1978-22843	19780802
	FR 2432316	B1	19820423		
	JP 55022687	A2	19800218	JP 1979-98151	19790802
PRAI	FR 1978-22843		19780802		
GI					



AB The title compds. I (n = 0, 1, 2, 3 and R = alkyl, or n = 1, 2, 3 and R = H, Cl, oxoalkyl, arylcarbonyl, CO2H, esterified CO2H, NH2, alkylamino, polymethylenimino; R1, R2, R3, R4, R5 = H, halo, NO2, NH2, Me, OMe) were prep'd. by different methods, and they exhibited anticholesteremic, anticonvulsant, antiarrhythmic, antiemetic, anti-ulcer, and cytostatic activity; one of the I also had an effect on blood coagulation. A mixt. of 5,2-Cl(MeO)C6H3SO2CH2CH2Cl (prep'd. from the resp. sulfide), piperidine, and Me2CHOH was refluxed to yield I (n = 2, R = piperidino, R1 = OMe, R4 = Cl, R2 = R3 = R5 = H).

IT 74254-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)


RN 74254-72-1 CAPLUS

CN Pyrrolidine, 1-[3-[(2-methoxyphenyl)sulfonyl]propyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 74254-71-0

CMF C14 H21 N O3 S



CRN 88-89-1
CMF C6 H3 N3 O7



L7 ANSWER 410 OF 478 CAPLUS COPYRIGHT 2003 ACS

AN 1981:461769 CAPLUS

DN 95:61769

TI Benzenesulfone derivatives and their use

IN Fournier, Jean Paul; Loiseau, Philippe

PA Choay S. A., Fr.

SO Fr. Demande, 19 pp.

CODEN: FRXXBL



DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2447909	A1	19800829	FR 1979-2572	19790131
	FR 2447909	B1	19821029		
PRAI	FR 1979-2572		19790131		

GI



II

AB Sulfones I (R = H, alkyl, Cl, oxoalkyl, oxoaryl, optionally esterified CO2H, amino; R1-R5 = H, halogen, NO2, NH2, Me, OMe; n = 1-3) were prep'd. Thus, 5,2-Cl(MeO)C6H3NH2 was diazotized and thiolated and the thiol treated with BrCH2CH2Cl to give 5,2-Cl(MeO)C6H3SCH2CH2Cl which was treated with piperidine to give II. Various I had antitumor, antiemetic, hypoglycemic, anticonvulsant, anticoagulant, antiulcer and antifibrillatory activity.

IT 74254-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)


RN 74254-72-1 CAPLUS

CN Pyrrolidine, 1-[3-[(2-methoxyphenyl)sulfonyl]propyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 74254-71-0


CMF C14 H21 N O3 S




CM 2

CRN 88-89-1

CMF C6 H3 N3 O7






L7 ANSWER 317 OF 478 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:235290 CAPLUS
 DN 112:235290
 TI Preparation of 1,3-disubstituted pyrrolidines as serotonin (partial) agonists and antagonists
 IN Schohe, Rudolf; Seidel, Peter Rudolf; Traber, Jorg; Glaser, Thomas
 PA Bayer A.-G., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 50 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 338331	A1	19891025	EP 1989-106023	19890406
	EP 338331	B1	19921021		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	DE 3835291	A1	19891102	DE 1988-3835291	19881015
	AT 81652	E	19921115	AT 1989-106023	19890406
	ES 2045229	T3	19940116	ES 1989-106023	19890406
	US 5037841	A	19910806	US 1989-336977	19890412
	AU 8933059	A1	19891026	AU 1989-33059	19890414
	AU 625817	B2	19920716		
	IL 89973	A1	19930131	IL 1989-89973	19890417
	DK 8901864	A	19891020	DK 1989-1864	19890418
	JP 01311059	A2	19891215	JP 1989-96549	19890418
	ZA 8902823	A	19891227	ZA 1989-2823	19890418
	US 5274097	A	19931228	US 1991-682785	19910409
	US 5453437	A	19950926	US 1993-118376	19930908
PRAI	DE 1988-3812989		19880419		
	DE 1988-3835291		19881015		
	EP 1989-106023		19890406		
	US 1989-336927		19890412		
	US 1989-336977		19890412		
	US 1991-682785		19910409		
OS	CASREACT 112:235290; MARPAT 112:235290				
GI					

102



AB The title compds. [I; A = (fused) heteroaryl; B = cyano, CO₂R₁, CONR₂R₃, SO₂NR₂R₃, SOM₄, NR₅R₆, C.tplbond.CCH₂NR₅R₆; X = OCH₂, CH₂O, O; R₁ = H, C₁-12 alkyl, C₅-8 cycloalkyl, C₂-12 alkenyl, aryl, aralkyl; R₂, R₃ = H, C₁-17 alkyl, (un)substituted aryl, etc.; R₅, R₆ = COR₂, SO₂R₈, any of definitions for R₂, R₃; R₇ = NHR₉, C₁-12 alkyl, C₁-17 alkoxy, etc.; R₈ = C₅-8 cycloalkyl, (un)substituted C₁-12 alkyl, (un)substituted (hetero)aryl, NR₂R₃; R₉ = H, C₅-8 cycloalkyl, (un)substituted C₁-12 alkyl,

aralkyl, (hetero)aryl, etc.; NR₅R₆ can form a (fused) heterocyclic ring, e.g., Q₁, Q₂, etc.; n = 1-10; n = 0-2] and their salts were prep'd. as 5-hydroxytryptamine agonists, partial agonists (no data), and antagonists,

useful for treatment of serotonergic system-related CNS diseases. A mixt. of 3-(2-cyanophenoxy)pyrrolidine, 2-(4-bromobutyl)benzothiazol-3(2H)-

one-1,1-dioxide, and Et₃N in DMF was stirred 20 h at 45.degree. to give

II

which was converted to its oxalate. The latter in vitro antagonized serotonin with an inhibition const. Ki = 2 nM.


IT 127341-41-7P 127341-57-5P 127341-90-6P

127341-92-8P 127366-99-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as serotonin agonist or antagonist)


RN 127341-41-7 CAPLUS

CN Benzenesulfonamide, 4-fluoro-N-[3-[3-(2-methoxyphenoxy)-1-pyrrolidinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 127341-57-5 CAPLUS

CN Methanesulfonamide, N-[4-[3-(2-methoxyphenoxy)-1-pyrrolidinyl]butyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 127341-90-6 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, compd. with 3-(2-methoxyphenoxy)-N,N-dimethyl-1-pyrrolidineethanesulfonamide (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 127341-89-3

CMF C15 H24 N2 O4 S



CM 2


CRN 81-04-9
CMF C10 H8 O6 S2



RN 127341-92-8 CAPLUS
CN 1,5-Naphthalenedisulfonic acid, compd. with N,N-diethyl-3-(2-methoxyphenoxy)-1-pyrrolidineethanesulfonamide (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 127341-91-7
CMF C17 H28 N2 O4 S



CM 2


CRN 81-04-9
CMF C10 H8 O6 S2




RN 127366-99-8 CAPLUS

CN Benzenesulfonamide, 4-fluoro-N-[2-[3-(2-methoxyphenoxy)-1-pyrrolidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

L7 ANSWER 318 OF 478 CAPLUS COPYRIGHT 2003 ACS

AN 1990:198021 CAPLUS

DN 112:198021

TI Synthesis and pharmacological properties of new 2-oxo-1-pyrrolidineacetylguanidines


AU Malawska, Barbara; Gorczyca, Maria; Filipek, Barbara; Krupinska, Jolanta

CS Dep. Pharm. Chem., Med. Acad., Krakow, 31-065, Pol.

SO Acta Pharmaceutica Jugoslavica (1989), 39(3), 201-8

CODEN: APJUA8; ISSN: 0001-6667

DT Journal




#119
App's

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 119 OF 478 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:549267 CAPLUS
 DN 131:184861
 TI Preparation of histamine H3 receptor ligands
 IN Kalindjian, Sarkis Barret; Buck, Ildiko Maria; Linney, Ian Duncan; Watt, Gillian Fairfull; Harper, Elaine Anne; Shankley, Nigel Paul
 PA James Black Foundation Limited, UK
 SO PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942458	A1	19990826	WO 1999-GB464	19990215
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318836	AA	19990826	CA 1999-2318836	19990215
	AU 9925354	A1	19990906	AU 1999-25354	19990215
	AU 747804	B2	20020523		
	BR 9908074	A	20001024	BR 1999-8074	19990215
	EP 1056733	A1	20001206	EP 1999-905049	19990215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002504483	T2	20020212	JP 2000-532410	19990215
	ZA 9901356	A	20000821	ZA 1999-1356	19990219
	NO 2000003918	A	20001003	NO 2000-3918	20000802
PRAI	GB 1998-3536	A	19980219		
	WO 1999-GB464	W	19990215		
OS	MARPAT 131:184861				
GI					



AB Title compds. [I; A represents $(CH_2)_m$, m being from 1 to 3; B is $(CH_2)_n$, n

being from 1 to 3; p is from 0 to 2; R1 is C1 to C10 hydrocarbyl, in which

up to 2 carbon atoms may be replaced by O, S or N; and up to 2 hydrogen atoms may be replaced by halogen; R2 is H or C1 to C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O, S or N, and up to 3 hydrogen atoms may be replaced by halogen; R3 is absent when -Y-Z-R2 is attached to W, or is H or C1 to C7 hydrocarbyl when -Y-Z-R2 is not attached to W; W is nitrogen; X is -CH2-, -O- or -NR4-, R4 being H or C1 to C3 alkyl; Y replaces a hydrogen atom on any of A, B, W and X, and is

C2 to C10 alkylene, in which one non-terminal carbon atom may be replaced by O; and Z is $-N(R_5)SO_2-$, $-SO_2N(R_6)-$, $-N(R_5)SO_2N(R_6)-$, $-N(R_5)C(:NQ)N(R_7)-$, $-N(R_5)S(:O)-$, $-SO_2-$ wherein R5, R6 and R7 are independently H or C1 to

C15 hydrocarbyl, in which up to 3 carbon atoms may be replaced by O or N, and up to 3 hydrogen atoms may be replaced by halogen, and Q is H or Me, or

Q is linked to R5 or R7 to form a five-membered ring or Q is linked to R2 to


form a six-membered ring] and pharmaceutically acceptable salts thereof are prep'd. and tested as histamine H3 receptor ligands. Thus, the title compd. II was prep'd.

IT 239481-22-2P 239481-23-3P 239481-24-4P
 239481-25-5P 239481-26-6P 239481-27-7P
 239481-28-8P 239481-29-9P 239481-30-2P
 239481-31-3P 239481-32-4P 239481-33-5P
 239481-35-7P 239481-37-9P 239481-38-0P
 239481-39-1P 239481-40-4P 239481-41-5P
 239481-42-6P 239481-43-7P 239481-44-8P
 239481-45-9P 239481-46-0P 239481-47-1P
 239481-48-2P 239481-49-3P 239481-50-6P
 239481-51-7P 239481-52-8P 239481-53-9P
 239481-54-0P 239481-55-1P 239481-56-2P
 239481-57-3P 239481-58-4P 239481-59-5P
 239481-60-8P 239481-61-9P 239481-62-0P
 239481-63-1P 239481-64-2P 239481-65-3P
 239481-66-4P 239481-67-5P 239481-68-6P
 239481-69-7P 239481-70-0P 239481-71-1P
 239481-73-3P 239481-74-4P 239481-75-5P
 239481-76-6P 239481-77-7P 239481-78-8P
 239481-79-9P 239481-80-2P 239481-84-6P
 239481-85-7P 239481-86-8P 239481-87-9P
 239481-88-0P 239481-89-1P 239481-90-4P

239481-91-5P 239481-93-7P 239481-94-8P
239481-95-9P 239481-96-0P 239481-97-1P
239481-98-2P 239481-99-3P 239482-00-9P
239482-01-0P 239482-02-1P 239482-03-2P
239482-06-5P 239482-07-6P 239482-09-8P
239482-14-5P 239482-15-6P 239482-16-7P
239482-17-8P 239482-18-9P 239482-19-0P
239482-20-3P 239482-21-4P 239482-22-5P
239482-23-6P 239482-24-7P 239482-25-8P
239482-26-9P 239482-27-0P 239482-28-1P
239482-29-2P 239482-30-5P 239482-31-6P
239482-32-7P 239482-33-8P 239482-34-9P
239482-35-0P 239482-36-1P 239482-37-2P
239482-38-3P 239482-39-4P 239482-40-7P
239482-41-8P 239482-42-9P 239482-43-0P
239482-44-1P 239482-45-2P 239482-46-3P
239482-47-4P 239482-48-5P 239482-49-6P
239482-50-9P 239482-51-0P 239482-52-1P
239482-53-2P 239482-54-3P 239482-55-4P
239482-59-8P 239482-60-1P 239482-61-2P
239482-62-3P 239482-63-4P


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(prepn. of histamine H3 receptor antagonists)

RN 239481-22-2 CAPLUS
CN Guanidine, [3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX
NAME)




●2 HCl

RN 239481-23-3 CAPLUS
CN Guanidine, N-[(4-chlorophenyl)methyl]-N'-[3-(1-pyrrolidinyl)propyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-24-4 CAPLUS

CN Guanidine, N-[(4-methoxyphenyl)methyl]-N'-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-25-5 CAPLUS


CN Guanidine, N-(2-naphthalenylmethyl)-N'-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 239481-26-6 CAPLUS

CN Guanidine, N-[3-(1-pyrrolidinyl)propyl]-N'-[4-(trifluoromethyl)phenylmethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-27-7 CAPLUS

CN Guanidine, N-[(4-iodophenyl)methyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-28-8 CAPLUS

CN Guanidine, N-[(3-bromo-4-methoxyphenyl)methyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-29-9 CAPLUS


CN Guanidine, N-(phenylmethyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-30-2 CAPLUS


CN Guanidine, N-[4-bromophenylmethyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-31-3 CAPLUS


CN Guanidine, N-[3-bromophenylmethyl]-N'-(3-(1-pyrrolidinyl)propyl)-,

dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-32-4 CAPLUS

CN Guanidine, N-[(2-bromophenyl)methyl]-N'-[3-(1-pyrrolidinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-33-5 CAPLUS

CN Guanidine, N-([1,1'-biphenyl]-4-ylmethyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-35-7 CAPLUS

CN Benzoic acid, 4-[[[imino[[3-(1-pyrrolidinyl)propyl]amino]methyl]amino]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-37-9 CAPLUS

CN Guanidine, N-[(4-chlorophenyl)methyl]-N'-[2-(1-pyrrolidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-38-0 CAPLUS

CN Guanidine, N-[(4-chlorophenyl)methyl]-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-39-1 CAPLUS

CN Guanidine, N-[(4-chlorophenyl)methyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-40-4 CAPLUS

CN Guanidine, N-(4-chlorophenyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-41-5 CAPLUS

CN Guanidine, N-[2-(4-chlorophenyl)ethyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-42-6 CAPLUS

CN Guanidine, N-[3-(4-chlorophenyl)propyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-43-7 CAPLUS

CN Guanidine, N-(4-phenylbutyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-44-8 CAPLUS

CN Guanidine, N-[2-(4-chlorophenyl)ethyl]-N'-[2-(1-pyrrolidinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●2 HCl


RN 239481-45-9 CAPLUS

CN Guanidine, N-[2-(4-chlorophenyl)ethyl]-N'-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-46-0 CAPLUS

CN Guanidine, N-[2-(4-chlorophenyl)ethyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-47-1 CAPLUS

CN Guanidine, N-[2-(4-bromophenyl)ethyl]-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-48-2 CAPLUS


CN Guanidine, N-[(4-chlorophenyl)methyl]-N'-(2-(1-methyl-2-pyrrolidinyl)ethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-49-3 CAPLUS


CN Guanidine, N-[3-(1-pyrrolidinyl)propyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-50-6 CAPLUS


CN Guanidine, N-[4-(1-pyrrolidinyl)butyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-51-7 CAPLUS


CN Guanidine, N-[5-(1-pyrrolidinyl)pentyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-52-8 CAPLUS


CN Guanidine, N-[6-(1-pyrrolidinyl)hexyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-53-9 CAPLUS


CN Guanidine, N-[7-(1-pyrrolidinyl)heptyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-54-0 CAPLUS


CN Guanidine, N-[3-(1-pyrrolidinyl)propyl]-N'-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-55-1 CAPLUS


CN Guanidine, N-[3-(1-pyrrolidinyl)propyl]-N'-(3-tricyclo[3.3.1.13,7]dec-1-ylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-56-2 CAPLUS


CN Guanidine, N-[4-(1-pyrrolidinyl)butyl]-N'-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-57-3 CAPLUS


CN Guanidine, N-[4-(1-pyrrolidinyl)butyl]-N'-(3-tricyclo[3.3.1.13,7]dec-1-ylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-58-4 CAPLUS


CN Guanidine, N-[5-(1-pyrrolidinyl)pentyl]-N'-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-59-5 CAPLUS


CN Guanidine, N-[5-(1-pyrrolidinyl)pentyl]-N'-(3-tricyclo[3.3.1.13,7]dec-1-ylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-60-8 CAPLUS


CN Guanidine, N-(cyclohexylmethyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 239481-61-9 CAPLUS

CN Guanidine, N-(cyclohexylmethyl)-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-62-0 CAPLUS

CN Guanidine, N-(cyclohexylmethyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-63-1 CAPLUS

CN Guanidine, N-(2-cyclohexylethyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-64-2 CAPLUS


CN Guanidine, N-(3-cyclohexylpropyl)-N'-(3-(1-pyrrolidinyl)propyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-65-3 CAPLUS

CN Guanidine, N-[(1R)-1-cyclohexylethyl]-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 239481-66-4 CAPLUS

CN Guanidine, N-[(1S)-1-cyclohexylethyl]-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 239481-67-5 CAPLUS


CN Guanidine, N-(cycloheptylmethyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-68-6 CAPLUS


CN Guanidine, N-(phenylmethyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-69-7 CAPLUS


CN Guanidine, N-[(2-methylphenyl)methyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-70-0 CAPLUS

CN Guanidine, N-[(1S)-1-phenylethyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 239481-71-1 CAPLUS

CN Guanidine, N-methyl-N-[(2-methylphenyl)methyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-73-3 CAPLUS


CN Guanidine, N,N'-bis[(4-chlorophenyl)methyl]-N-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-74-4 CAPLUS


CN Guanidine, N-(2-naphthalenylmethyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-75-5 CAPLUS

CN Guanidine, N-((1,1'-biphenyl)-4-ylmethyl)-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-76-6 CAPLUS


CN Guanidine, N-((1,1'-biphenyl)-4-ylmethyl)-N'-(5-(1-pyrrolidinyl)pentyl)-

dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-77-7 CAPLUS

CN Guanidine, N-[(4-cyclohexylphenyl)methyl]-N'-(4-(1-pyrrolidinyl)butyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-78-8 CAPLUS

CN Guanidine, N-[(4-cyclohexylphenyl)methyl]-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239481-79-9 CAPLUS

CN Guanidine, N-[5-(1-pyrrolidinyl)pentyl]-N'-(tetrahydro-2H-pyran-2-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 239481-80-2 CAPLUS


CN Guanidine, N-[2-[2-(1-pyrrolidinyl)ethoxy]ethyl]-N'-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 239481-84-6 CAPLUS

CN Guanidine, N'-(4-chlorophenylmethyl)-N-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 239481-85-7 CAPLUS

CN Guanidine, N-butyl-N'-(5-(1-pyrrolidinyl)pentyl)- (9CI) (CA INDEX NAME)



RN 239481-86-8 CAPLUS


CN Guanidine, N-(3-methylbutyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-87-9 CAPLUS


CN Guanidine, N-(2-methylbutyl)-N'-(5-(1-pyrrolidinyl)pentyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-88-0 CAPLUS


CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-89-1 CAPLUS

CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[5-(1-pyrrolidinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-90-4 CAPLUS

CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[6-(1-pyrrolidinyl)hexyl]-,


dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-91-5 CAPLUS


CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[7-(1-pyrrolidinyl)heptyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-93-7 CAPLUS


CN Guanidine, N-[(phenylmethyl)-N-[6-(1-pyrrolidinyl)hexyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239481-94-8 CAPLUS

CN Guanidine, N-[(4-bromophenyl)methyl]-N-[6-(1-pyrrolidinyl)hexyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-95-9 CAPLUS

CN Guanidine, N-[(1S)-1-phenylethyl]-N-[5-(1-pyrrolidinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 239481-96-0 CAPLUS

CN Guanidine, N-[(2-methylphenyl)methyl]-N-[6-(1-pyrrolidinyl)hexyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-97-1 CAPLUS
 CN Guanidine, N-[6-(1-pyrrolidinyl)hexyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239481-98-2 CAPLUS
 CN Guanidine, N-[6-(1-pyrrolidinyl)hexyl]-N-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 239481-99-3 CAPLUS
 CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[8-(1-pyrrolidinyl)octyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 239482-00-9 CAPLUS


CN Guanidine, N-[(4-chlorophenyl)methyl]-N-[9-(1-pyrrolidinyl)nonyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 239482-01-0 CAPLUS

CN 2-Naphthalenesulfonamide, N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 239482-02-1 CAPLUS


CN 2-Naphthalenesulfonamide, N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 239482-03-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX
NAME)



RN 239482-06-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 239482-07-6 CAPLUS
CN 2-Naphthalenesulfinamide, N-[3-(1-pyrrolidinyl)propyl]-,
monohydrochloride
(9CI) (CA INDEX NAME)




• HCl


RN 239482-09-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 239482-14-5 CAPLUS
CN 1-Naphthalenesulfonamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 239482-15-6 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)




RN 239482-16-7 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)



RN 239482-17-8 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[2-[(2S)-1-methyl-2-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-18-9 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-19-0 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-20-3 CAPLUS

CN Benzenemethanesulfonamide, N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-21-4 CAPLUS

CN Benzenemethanesulfonamide, 4-bromo-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-22-5 CAPLUS

CN Benzeneethanesulfonamide, 4-chloro-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-23-6 CAPLUS

CN Benzenepropanesulfonamide, 4-chloro-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-24-7 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[4-[(2S)-1-methyl-2-pyrrolidinyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-25-8 CAPLUS


CN Benzenemethanesulfonamide, 4-chloro-N-[5-[(2S)-1-methyl-2-pyrrolidinyl]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 239482-26-9 CAPLUS


CN Benzenemethanesulfonamide, 4-chloro-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 239482-27-0 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-28-1 CAPLUS

CN Sulfamide, N-[(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-29-2 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-(3-[(2R)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-30-5 CAPLUS

CN Sulfamide, N-(cyclohexylmethyl)-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-31-6 CAPLUS

CN Sulfamide, N-[2-(4-chlorophenyl)ethyl]-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-32-7 CAPLUS

CN Sulfamide, N-(4-chlorophenyl)-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-33-8 CAPLUS

CN Sulfamide, N-[(4-bromophenyl)methyl]-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-34-9 CAPLUS

CN Sulfamide, N-[(4-iodophenyl)methyl]-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-35-0 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[2-[(2S)-1-methyl-2-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-36-1 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[4-[(2S)-1-methyl-2-pyrrolidinyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-37-2 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[5-[(2S)-1-methyl-2-pyrrolidinyl]pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-38-3 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[3-[(2S)-1-[3-(4-chlorophenyl)propyl]-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-39-4 CAPLUS

CN Sulfamide, N-[4-chlorophenyl]methyl]-N'-(3-[(2S)-1-(1-methylpropyl)-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-40-7 CAPLUS

CN Sulfamide, N-[4-chlorophenyl]methyl]-N,N'-dimethyl-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-41-8 CAPLUS

CN Sulfamide, N-[4-chlorophenyl]methyl]-N-methyl-N'-(3-[(2S)-1-methyl-2-pyrrolidinyl]propyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-42-9 CAPLUS

CN Sulfamide, N'-(4-chlorophenyl)methyl]-N-methyl-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-43-0 CAPLUS

CN Glycine, N-[[[(4-chlorophenyl)methyl]amino]sulfonyl]-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-44-1 CAPLUS

CN Sulfamide, N'-(4-chlorophenyl)methyl]-N-(2-hydroxyethyl)-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-45-2 CAPLUS

CN Sulfamide, N'-(4-chlorophenyl)methyl]-N-[3-(1,3-dihydro-1,3-dioxo-2H-isooindol-2-yl)propyl]-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-46-3 CAPLUS

CN Sulfamide, N-(3-aminopropyl)-N'-(4-chlorophenyl)methyl]-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-47-4 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)methyl]amino]sulfonyl][3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]amino]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-48-5 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)methyl]amino]sulfonyl][3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-49-6 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)methyl]-2-[[[[(4-chlorophenyl)methyl]amino]sulfonyl][3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-50-9 CAPLUS

CN Glycine, N-[[[(4-chlorophenyl)methyl]amino]sulfonyl]-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-51-0 CAPLUS

CN Sulfamide, N'-(4-chlorophenyl)methyl]-N-[3-(4-chlorophenyl)propyl]-N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239482-52-1 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-(3-[(2S,4R)-4-hydroxy-1-methyl-2-

pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239482-53-2 CAPLUS


CN Sulfamide, N-[3-[(2S,4R)-4-[(4-chlorophenyl)methoxy]-1-methyl-2-pyrrolidinyl]propyl]-N'-(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239482-54-3 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-(2-(1-pyrrolidinyl)ethyl)- (9CI) (CA INDEX NAME)



RN 239482-55-4 CAPLUS


CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-(3-(1-pyrrolidinyl)propyl)- (9CI) (CA INDEX NAME)



RN 239482-59-8 CAPLUS


CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[4-(1-pyrrolidinyl)butyl]-
(9CI)

(CA INDEX NAME)




RN 239482-60-1 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N,N'-bis[4-(1-pyrrolidinyl)butyl]-
(9CI) (CA INDEX NAME)




RN 239482-61-2 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[5-(1-pyrrolidinyl)pentyl]-
(9CI)
(CA INDEX NAME)




RN 239482-62-3 CAPLUS
CN Cyclohexaneethanesulfonamide, N-[3-[(2S)-1-methyl-2-pyrrolidinyl]propyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239482-63-4 CAPLUS
CN Benzenemethanesulfonamide, 4-chloro-N-[3-[(2S)-1-(1-methylpropyl)-2-pyrrolidinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 239483-58-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of histamine H3 receptor antagonists)
RN 239483-58-0 CAPLUS
CN Sulfamide, N-[(4-chlorophenyl)methyl]-N'-[3-(2S)-2-pyrrolidinylpropyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 239482-64-5P 239482-66-7P 239482-68-9P
239482-73-6P 239482-76-9P 239482-82-7P
239482-87-2P 239482-90-7P 239482-94-1P
239483-10-4P 239483-14-8P 239483-15-9P
239483-16-0P 239483-17-1P 239483-20-6P
239483-22-8P 239483-23-9P 239483-24-0P
239483-25-1P 239483-26-2P 239483-27-3P
239483-28-4P 239483-29-5P 239483-30-8P
239483-31-9P 239483-32-0P 239483-37-5P
239483-40-0P 239483-41-1P 239483-43-3P
239483-49-9P 239483-52-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
RACT (Reactant or reagent)

(prepn. of histamine H3 receptor antagonists)
RN 239482-64-5 CAPLUS
CN Carbamic acid, [(3-(1-pyrrolidinyl)propyl)carbonimidoyl]bis-,
bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 239482-66-7 CAPLUS
CN Carbamic acid, [(4-chlorophenyl)methyl][[[(1,1-dimethylethoxy)carbonyl]amino][[3-(1-pyrrolidinyl)propyl]imino]methyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 239482-68-9 CAPLUS

CN Carbamic acid, [[[[(1,1-dimethylethoxy)carbonyl]amino][[3-(1-pyrrolidinyl)propyl]imino]methyl][(4-methoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 239482-73-6 CAPLUS

CN Carbamic acid, [(4-chlorophenyl)methyl] [[[[(1,1-dimethylethoxy)carbonyl]amino][[4-(1-pyrrolidinyl)butyl]imino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 239482-76-9 CAPLUS

CN Carbamic acid, [[[[(1,1-dimethylethoxy)carbonyl]imino][methyl(phenylmethyl)amino]methyl][5-(1-pyrrolidinyl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239482-82-7 CAPLUS


CN Carbamic acid, [(4-chlorophenyl)methyl][[[(4-chlorophenyl)methyl][4-(1-pyrrolidinyl)butyl]amino][[(1,1-dimethylethoxy)carbonyl]imino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 239482-87-2 CAPLUS

CN Carbamic acid, [[[(4-chlorophenyl)methyl][4-(1-


pyrrolidinyl)butyl]amino] [[(1,1-
dimethylethoxy)carbonyl]amino]methylene]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239482-90-7 CAPLUS
CN Carbamic acid, [[[[(4-chlorophenyl)methyl][5-(1-
pyrrolidinyl)pentyl]amino] [[(1,1-
dimethylethoxy)carbonyl]amino]methylene]-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 239482-94-1 CAPLUS
CN Carbamic acid, [[[[(1,1-dimethylethoxy)carbonyl]amino] [[6-(1-
pyrrolidinyl)hexyl] (tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]methylene]-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239483-10-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[2-[(4-


chlorophenyl) (methylsulfonyl)amino]
ethyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239483-14-8 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[5-[(4-chlorophenyl)(methylsulfonyl)amino]pentyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239483-15-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-(9,9-dimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl)-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 239483-16-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[6-[(4-chlorophenyl)methyl]-9,9-dimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-17-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[(1,1-dimethylethoxy)carbonyl]amino]sulfonyl]amino]propyl]-, 1,1-dimethylethyl ester, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-20-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[(4-chlorophenyl)methyl]amino]sulfonyl]amino]propyl]-, 1,1-dimethylethyl ester, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-22-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-(10,10-dimethyl-6,6-dioxido-8-oxo-9-oxa-6-thia-5,7-diazaundec-1-yl)-, 1,1-dimethylethyl ester, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239483-23-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[7-[(4-chlorophenyl)methyl]-10,10-dimethyl-

6,6-dioxido-8-oxo-9-oxa-6-thia-5,7-diazaundec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-24-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[5-[[[[[(4-chlorophenyl)methyl]amino]sulfonyl]((1,1-dimethylethoxy)carbonyl)amino]pentylyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-25-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[[[[[(4-chlorophenyl)methyl]methylamino]sulfonyl]methylamino]propyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-26-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[[[[4-chlorophenyl)methyl]amino]sulfonyl][(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-27-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[[[[4-chlorophenyl)methyl]methylamino]sulfonyl][(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-28-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[6-[(4-chlorophenyl)methyl]-4,9,9-trimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-29-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[6-[(4-chlorophenyl)methyl]-4-(2-methoxy-2-oxoethyl)-9,9-dimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-30-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[4-(carboxymethyl)-6-[(4-chlorophenyl)methyl]-9,9-dimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1-(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-31-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[6-[(4-chlorophenyl)methyl]-9,9-dimethyl-4-[2-(methylamino)-2-oxoethyl]-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-32-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[6-[(4-chlorophenyl)methyl]-4-[2-[(4-chlorophenyl)methyl]amino]-2-oxoethyl]-9,9-dimethyl-5,5-dioxido-7-oxo-8-oxa-5-thia-4,6-diazadec-1-yl]-, 1,1-dimethylethyl ester, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 239483-37-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[3-[[[[4-chlorophenyl)methyl]amino]sulfonyl][(1,1-dimethylethoxy)carbonyl]amino]propyl]-4-hydroxy-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 239483-40-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 4-[(4-chlorophenyl)methoxy]-2-[3-[[[[4-chlorophenyl)methyl]amino]sulfonyl][(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 239483-41-1 CAPIUS

CN 1-Pyrrolidinecarboxylic acid, 2-[4-[[[(4-chlorophenyl)methyl]amino]sulfonyl]3-butene-1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 239483-43-3 CAPIUS


CN 1-Pyrrolidinecarboxylic acid, 2-[4-[[[(4-chlorophenyl)methyl]amino]sulfonyl]butyl-1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 239483-49-9 CAPIUS


CN Carbamic acid, [[[[(4-chlorophenyl)methyl]amino]sulfonyl]4-(1-pyrrolidinyl)butyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239483-52-4 CAPLUS

CN Sulfamide, N-[(4-chlorophenyl)methyl]-N,N'-dimethyl-N'-(3-(2S)-2-pyrrolidinylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 120 OF 478 CAPLUS COPYRIGHT 2003 ACS

AN 1999:481300 CAPLUS

DN 131:129899

TI Preparation of nitrogen heterocyclic compounds as antiosteoporotic agents

IN Hagiwara, Koji; Suzuki, Koji; Okada, Fumio; Sugiyama, Tomomi; Kosaka, Nobuo

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11209344	A2	19990803	JP 1998-12428	19980126
PRAI	JP 1998-12428		19980126		
OS	MARPAT 131:129899				
GI					

and IV were prepd. by conventional methods in soln.
 IT **78452-36-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and sapon. of)
 RN 78452-36-5 CAPLUS
 CN L-Proline, 1-[N5-[imino[(2,4,6-trimethylphenyl)sulfonyl]amino]methyl]-
 N2- [(phenylmethoxy)carbonyl]-L-ornithyl-, methyl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




L33 ANSWER 162 OF 221 CAPLUS COPYRIGHT 2001 ACS

AN 1981:461994 CAPLUS
 DN 95:61994
 TI Benzenesulfonamide derivatives
 PA Bilfing, J. R., Fed. Rep. Ger.
 SO Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 55157564	A2	19801208	JP 1980-68776	19800523
	EP 21592	A1	19810107	EP 1980-301643	19800520
	EP 21592	B1	19830928		
R: AT, BE, CH, DE, FR, GB, IT, NL, SE					
DK	8002229	A	19801124	DK 1980-2229	19800521
ES	491762	A1	19810616	ES 1980-491762	19800522
AU	8058720	A1	19801127	AU 1980-58720	19800523
AU	531504	B2	19830825		
ZA	8003096	A	19810527	ZA 1980-3096	19800523
CA	1152508	A1	19830823	CA 1980-352567	19800523
US	4396622	A	19830802	US 1982-348212	19820212
US	4622331	A	19861111	US 1985-740175	19850531
PRAI	GB 1979-17892		19790523		
	US 1980-148140		19800509		
	US 1982-348212		19820212		
	US 1983-477071		19830321		

GI




AB Benzenesulfonamide derivs. (I; R2N = piperidino, pyrrolidino, N-methylpiperazino, morpholino derivs.; R1 = H, CF₃, halo; R2 = NH₂, NHAc, Me, OMe, etc.; n = 2, 3), effective antiarrhythmics at 32 mg/kg in guinea pigs, were prep'd. Thus, a mixt. of 21.9 g 4-AcNH₂C₆H₄SO₂Cl and 10.7 g 1-(2-aminoethyl)pyrrolidine in H₂O was stirred 9 h at room temp. and treated with EtOAc and HCl to give 78% I.HCl (R2N = pyrrolidino, R1 = H, R2 = NHAc, n = 2). Similarly prep'd. were 56 addnl. I.

IT 77283-30-8P 77283-31-9P 77283-32-0P
 77283-33-1P 77283-34-2P 77283-36-4P
 77283-39-7P 77283-40-0P 77283-41-1P
 77283-42-2P 77283-44-4P 77283-45-5P
 77283-46-6P 77283-47-7P 77283-48-8P
 77283-49-9P 77283-50-2P 77283-51-3P
 77283-53-5P 77283-54-6P 77283-55-7P
 77283-56-8P 77283-57-9P 77283-60-4P
 77283-61-5P 77283-64-8P 77283-65-9P
 77283-67-1P 77283-71-7P 77283-72-8P
 77283-73-9P 77283-74-0P 77283-77-3P
 77283-79-5P 77292-49-0P 77292-50-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation (prepn. and antiarrhythmic activity of))


RN 77283-30-8 CAPLUS

CN Acetamide, N-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 77283-31-9 CAPLUS


CN Acetamide, N-[4-[[[3-(1-pyrrolidinyl)propyl]amino]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-32-0 CAPLUS


CN Benzenesulfonamide, 4-amino-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 77283-33-1 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 77283-34-2 CAPLUS

CN Acetamide, N-[4-[[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 77283-36-4 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 77283-35-3


CMF C14 H23 N3 O2 S




CM 2

CRN 110-17-8
 CMF C4 H4 O4
 CDES 2:E ..

Double bond geometry as shown.




RN 77283-39-7 CAPLUS
 CN Benzenesulfonamide, 4-methyl-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 77283-40-0 CAPLUS
 CN Benzenesulfonamide, 4-methoxy-N-[2-(1-pyrrolidinyl)ethyl]-,

monohydrochloride (9CI) (CA INDEX NAME)



RN 77283-41-1 CAPLUS


CN Benzenesulfonamide, 4-methoxy-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-42-2 CAPLUS


CN Benzenesulfonamide, N-[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]-4-methoxy- monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-44-4 CAPLUS


CN Benzenesulfonamide, 4-fluoro-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 77283-45-5 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 77283-46-6 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 77283-47-7 CAPLUS


CN Benzenesulfonamide, 4-chloro-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-48-8 CAPLUS


CN Benzenesulfonamide, 4-bromo-N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 77283-49-9 CAPLUS

CN Benzenesulfonamide, 4-iodo-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 77283-50-2 CAPLUS


CN Benzenesulfonamide, 4-iodo-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-51-3 CAPLUS

CN Benzenesulfonamide, 4-(methylthio)-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 77283-53-5 CAPLUS

CN Benzoic acid, 4-[[[3-(1-pyrrolidinyl)propyl]amino]sulfonyl]-, ethyl ester,


monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-54-6 CAPLUS

CN Benzenesulfonamide, N-[2-(1-pyrrolidinyl)ethyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 77283-55-7 CAPLUS

CN Benzenesulfonamide, N-[2-(2,5-dimethyl-1-pyrrolidinyl)ethyl]-3-(trifluoromethyl)-, monohydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 77283-56-8 CAPLUS

CN Benzenesulfonamide, N-[2-(2,5-dimethyl-1-pyrrolidinyl)ethyl]-3-(trifluoromethyl)-, monohydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 77283-57-9 CAPLUS


CN Benzenesulfonamide, N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 77283-60-4 CAPLUS

CN Benzenesulfonamide, 2,5-dichloro-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl


RN 77283-61-5 CAPLUS
CN Benzenesulfonamide, 2,5-dichloro-N-[3-(2,4-dimethyl-1-pyrrolidinyl)propyl]-
(9CI) (CA INDEX NAME)



RN 77283-64-8 CAPLUS
CN Benzenesulfonamide, 2,4,5-trichloro-N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 77283-65-9 CAPLUS
CN Benzenesulfonamide, 2,4,5-trichloro-N-[3-(2,4-dimethyl-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl1

RN 77283-67-1 CAPLUS


CN Benzenesulfonamide, 2,4,5-trichloro-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl1

RN 77283-71-7 CAPLUS


CN Benzenesulfonamide, 2,4,6-trimethyl-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-72-8 CAPLUS


CN Benzenesulfonamide, N-[2-(2,4-dimethyl-1-pyrrolidinyl)ethyl]-2,4,6-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-73-9 CAPLUS


CN Benzenesulfonamide, N-[3-(2,4-dimethyl-1-pyrrolidinyl)propyl]-2,4,6-tris(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-74-0 CAPLUS


CN Benzenesulfonamide, N-[3-(2,5-dimethyl-1-pyrrolidinyl)propyl]-2,4,6-tris(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77283-77-3 CAPLUS

CN Benzenesulfonamide, 2,4,6-trimethyl-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 77283-79-5 CAPLUS

CN Benzenesulfonamide, 2,4,6-tris(1-methylethyl)-N-[2-(1-pyrrolidinyl)ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 77283-78-4

CMF C21 H36 N2 O2 S




CM 2

CRN 110-17-8

CMF C4 H4 O4


CDES 2:E

Double bond geometry as shown.




RN 77292-49-0 CAPLUS

CN Benzenesulfonamide, N-[3-(2,4-dimethyl-1-pyrrolidinyl)propyl]-4-iodo-
(9CI) (CA INDEX NAME)



RN 77292-50-3 CAPLUS

CN Benzenesulfonamide, 2,3,4-trichloro-N-[3-(2,4-dimethyl-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



L33 ANSWER 163 OF 221 CAPLUS COPYRIGHT 2001 ACS

AN 1981:424983 CAPLUS

DN 95:24983

TI Synthesis of N-(3-amino-2-hydroxy propyl)-N-sulfonylanilines derivatives.

Potential antianginal activities

AU Goldenberg, Charles; Van Meerbeeck, Clement; Wandestrick, Raymond; Descamps, Marcel; Tornay, Chantal; Dirks, Michel; Colot, Michel; De Claviere, Michel

CS Cent. Rech. S.A., Labaz N.V., Brussels, B-1120, Belg.

SO Eur. J. Med. Chem. - Chim. Ther. (1980), 15(6), 545-50
CODEN: EJMCA5; ISSN: 0009-4374

DT Journal

LA French